Page 1610 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 87 Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma 1431.e5

184. Rummel MJ, Lerchenmüller C, Greil R, et al: Bendamustine-rituximab IgM flare, as well as plasmapheresis in patients with Waldenström’s
induction followed by observation or rituximab maintenance for newly macroglobulinemia. Clin Lymphoma Myeloma 9:56, 2009.
diagnosed patients with waldenström’s macroglobulinemia: results from 192. Gobbi PG, Bettini R, Montecucco C, et al: Study of prognosis in
a prospective, randomized, multicenter study (StiL NHL 7-2008). Waldenström’s macroglobulinemia: a proposal for a simple binary
Blood 120:2739, 2012. classification with clinical and investigational utility. Blood 83:2939,
185. Kyriakou C, Canals C, Sibon D, et al: High-dose therapy and autolo- 1994.
gous stem-cell transplantation in Waldenström macroglobulinemia: the 193. Morel P, Monconduit M, Jacomy D, et al: Prognostic factors in
Lymphoma Working Party of the European Group for Blood and Waldenström macroglobulinemia: a report on 232 patients with the
Marrow Transplantation. J Clin Oncol 28:2227, 2010. description of a new scoring system and its validation on 253 other
186. Kyriakou C, Canals C, Cornelissen JJ, et al: Allogeneic stem-cell trans- patients. Blood 96:852, 2000.
plantation in patients with Waldenström macroglobulinemia: report 194. Dhodapkar MV, Jacobson JL, Gertz MA, et al: Prognostic factors
from the Lymphoma Working Party of the European Group for Blood and response to fludarabine therapy in patients with Waldenström
and Marrow Transplantation. J Clin Oncol 28:4926, 2010. macroglobulinemia: results of United States intergroup trial (Southwest
187. Owen RG, Kyle RA, Stone MJ, et al: Response assessment in Walden- Oncology Group S9003). Blood 98:41, 2001.
ström macroglobulinemia. Br J Haematol 160:171, 2013. 195. Dimopoulos M, Gika D, Zervas K, et al: The international staging
188. Treon SP, Yang G, Hanzis C, et al: Attainment of complete/very good system for multiple myeloma is applicable in symptomatic Walden-
partial response following rituximab based therapy is an important ström’s macroglobulinemia. Leuk Lymphoma 45:1809, 2004.
determinant to progression-free survival and is impacted by poly- 196. Anagnostopoulos A, Zervas K, Kyrtsonis M, et al: Prognostic value
morphisms in FCGR3A in Waldenström macroglobulinaemia. Br J of serum beta 2-microglobulin in patients with Waldenström’s mac-
Haematol 154:223, 2011. roglobulinemia requiring therapy. Clin Lymphoma Myeloma 7:205,
189. Strauss SJ, Maharaj L, Hoare S, et al: Bortezomib therapy in patients 2006.
with relapsed or refractory lymphoma: potential correlation of in vitro 197. Morel P, Duhamel A, Gobbi P, et al: International prognostic scoring
sensitivity and tumor necrosis factor alpha response with clinical activ- system for Waldenström macroglobulinemia. Blood 113:4163, 2009.
ity. J Clin Oncol 24:2105, 2006. 198. Kastritis S, Kyrtsonis MC, Hatjiharissi E, et al: No significant improve-
190. Varghese AM, Rawstron AC, Ashcroft J, et al: Assessment of bone ment in the outcome of patients with Waldenström macroglobulinemia
marrow response in Waldenström’s macroglobulinemia. Clin Lymphoma treated over the last 25 years. Am J Hematol 86:479, 2011.
Myeloma 9:53, 2009.
191. Ciccarelli BT, Yang G, Hatjiharissi E, et al: Soluble CD27 is a faithful
marker of disease burden and is unaffected by the rituximab induced